The 1st European HRA Meeting
(12th Hepatocyte Research Association Meeting)
@ISSX Europe
Cologne, Germany
June 27, 2017 @ 1800
Gürzenich Köln, Kleiner Saal Ballroom

Register by emailing us at hepaticproducts@qps.com
REGISTRATION IS LIMITED TO THE FIRST 75 ATTENDEES

ORGANIZING COMMITTEE
Shiloh J. Barfield – QPS Hepatic Biosciences
Matt Sherman – Lonza
Gary Hingorani, PhD – Array Biopharma
Ji Young Lee, PhD – Yecuris
Susan Wong – Genentech
Gillian Wallace, PhD – Thermo Fisher
Jeff Oakes – Qualyst
Ylva Terelius, PhD – Karolinska Institute
Diane Ramsden – Boehringer-Ingelheim
Scott Heyward – IVT/Bioreclamation
**Hepatocyte Research Association (HRA)**

**12th Annual Meeting**

Tuesday, June 27, 2017 @ ISSX Europe – Cologne

Gürzenich Köln, Kleiner Saal Ballroom

**“Strategies for Hepatic Infectious Disease Research”**

<table>
<thead>
<tr>
<th>TIME</th>
<th>TITLE/TOPIC</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>1800 - 1830</td>
<td>ATTENDEE CHECK IN (name badge, prospectus, refreshments)</td>
<td>Shiloh Barfield</td>
</tr>
<tr>
<td>1830 - 1900</td>
<td>3D microfluidic liver cultures for the study of hepatitis B virus infection</td>
<td>Marcus Dorner, PhD</td>
</tr>
<tr>
<td>1900 - 1915</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>1915 - 1945</td>
<td>Liver humanized FRG mice: a model to study human hepatic infectious diseases</td>
<td>Lander Foquet, PhD</td>
</tr>
<tr>
<td>1945 – 2000</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>2000 - 2030</td>
<td>HμRELviral™: A New Primary Hepatocyte-Based Tool for Studying Hepatitis B Viral Chronicity</td>
<td>Eric Novik, PhD</td>
</tr>
<tr>
<td>2030 - 2045</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>2045 - 2200</td>
<td>Cocktail &amp; Hors d’oeuvre Reception for Attendees, Speakers, &amp; Organizers</td>
<td></td>
</tr>
</tbody>
</table>

*The HRA is classified as a non-profit organization with 501(c)3 status*
Speaker Biographies

**Marcus Dorner** is a Non-Clinical Senior Lecturer in Immunology and head of hepatitis virus research at Imperial College London. Following on from his time at the Rockefeller University (New York), where he worked with Charles Rice on the development of a genetically humanized HCV mouse model as well as the delineation of innate immune responses for hepatitis C virus, his group now focuses on developing novel model systems for hepatitis B virus. His primary research interests are the identification of host/pathogen interactions and innate immune evasion strategies governing viral persistence using both, in vitro and in vivo model systems.

**Lander Foquet, PhD, Study Director, Seventh Wave Laboratories**, specialized in working with the FRG humanized liver mouse model from Yecuris. Here, he applies the humanized mouse model for studies on infectious diseases (viral hepatitis, malaria), gene delivery, and drug metabolism. After obtaining his PhD at Ghent University for his work on the development of a humanized mouse model for malaria, he continued his work on malaria as a post-doctoral researcher with a fellowship of the Belgian American Educational Foundation at the Center for Infectious Disease Research in Seattle.

**Eric Novik, PhD**, Chief Scientific Officer, Dr. Novik manages HµREL’s R&D and production functions, and he also serves as the principal scientific liaison to HµREL’s customers. He has played a seminal role in the invention, development, and characterization of HµREL’s Hµrelhuman™ and eight pre-clinical species’ hepatic co-cultures, its patent-pending Hµrelflux™ single-well biliary efflux assay, and its Hµrelviral™ platform for the study of HBV and other hepatotropic (viral) pathogens; as well as of the Company’s Hµrelflow™ multi-tissue microfluidic platform. Dr. Novik holds a Ph.D. in biomedical engineering from Rutgers University.